These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

504 related items for PubMed ID: 20370682

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Estrogen-functionalized liposomes grafted with glutathione-responsive sheddable chotooligosaccharides for the therapy of osteosarcoma.
    Yin X, Feng S, Chi Y, Liu J, Sun K, Guo C, Wu Z.
    Drug Deliv; 2018 Nov; 25(1):900-908. PubMed ID: 29644882
    [Abstract] [Full Text] [Related]

  • 4. Vascular targeting of doxorubicin using cationic liposomes.
    Wu J, Lee A, Lu Y, Lee RJ.
    Int J Pharm; 2007 Jun 07; 337(1-2):329-35. PubMed ID: 17275230
    [Abstract] [Full Text] [Related]

  • 5. One platform comparison of estrone and folic acid anchored surface engineered MWCNTs for doxorubicin delivery.
    Mehra NK, Jain NK.
    Mol Pharm; 2015 Feb 02; 12(2):630-43. PubMed ID: 25517904
    [Abstract] [Full Text] [Related]

  • 6. Doxorubicin-loaded nanocarriers: A comparative study of liposome and nanostructured lipid carrier as alternatives for cancer therapy.
    Fernandes RS, Silva JO, Monteiro LOF, Leite EA, Cassali GD, Rubello D, Cardoso VN, Ferreira LAM, Oliveira MC, de Barros ALB.
    Biomed Pharmacother; 2016 Dec 02; 84():252-257. PubMed ID: 27664949
    [Abstract] [Full Text] [Related]

  • 7. Improved drug delivery and therapeutic efficacy of PEgylated liposomal doxorubicin by targeting anti-HER2 peptide in murine breast tumor model.
    Zahmatkeshan M, Gheybi F, Rezayat SM, Jaafari MR.
    Eur J Pharm Sci; 2016 Apr 30; 86():125-35. PubMed ID: 26972276
    [Abstract] [Full Text] [Related]

  • 8. A comparative study of folate receptor-targeted doxorubicin delivery systems: dosing regimens and therapeutic index.
    Scomparin A, Salmaso S, Eldar-Boock A, Ben-Shushan D, Ferber S, Tiram G, Shmeeda H, Landa-Rouben N, Leor J, Caliceti P, Gabizon A, Satchi-Fainaro R.
    J Control Release; 2015 Jun 28; 208():106-20. PubMed ID: 25869964
    [Abstract] [Full Text] [Related]

  • 9. Targeted delivery of doxorubicin using stealth liposomes modified with transferrin.
    Li X, Ding L, Xu Y, Wang Y, Ping Q.
    Int J Pharm; 2009 May 21; 373(1-2):116-23. PubMed ID: 19429296
    [Abstract] [Full Text] [Related]

  • 10. Hyaluronic acid modified pH-sensitive liposomes for targeted intracellular delivery of doxorubicin.
    Paliwal SR, Paliwal R, Agrawal GP, Vyas SP.
    J Liposome Res; 2016 Dec 21; 26(4):276-87. PubMed ID: 26784587
    [Abstract] [Full Text] [Related]

  • 11. Polyethylene glycol-complexed cationic liposome for enhanced cellular uptake and anticancer activity.
    Jung SH, Jung SH, Seong H, Cho SH, Jeong KS, Shin BC.
    Int J Pharm; 2009 Dec 01; 382(1-2):254-61. PubMed ID: 19666094
    [Abstract] [Full Text] [Related]

  • 12. Tamoxifen guided liposomes for targeting encapsulated anticancer agent to estrogen receptor positive breast cancer cells: in vitro and in vivo evaluation.
    Jain AS, Goel PN, Shah SM, Dhawan VV, Nikam Y, Gude RP, Nagarsenker MS.
    Biomed Pharmacother; 2014 May 01; 68(4):429-38. PubMed ID: 24721327
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Reversibly crosslinked hyaluronic acid nanoparticles for active targeting and intelligent delivery of doxorubicin to drug resistant CD44+ human breast tumor xenografts.
    Zhong Y, Zhang J, Cheng R, Deng C, Meng F, Xie F, Zhong Z.
    J Control Release; 2015 May 10; 205():144-54. PubMed ID: 25596560
    [Abstract] [Full Text] [Related]

  • 15. Co-delivery of epirubicin and paclitaxel using an estrone-targeted PEGylated liposomal nanoparticle for breast cancer.
    Tang H, Chen J, Wang L, Li Q, Yang Y, Lv Z, Bao H, Li Y, Luan X, Li Y, Ren Z, Zhou X, Cong D, Liu Z, Jia J, Chen H, Zhao W, Meng Q, Sun F, Pei J.
    Int J Pharm; 2020 Jan 05; 573():118806. PubMed ID: 31678519
    [Abstract] [Full Text] [Related]

  • 16. Improved therapeutic activity of folate-targeted liposomal doxorubicin in folate receptor-expressing tumor models.
    Gabizon A, Tzemach D, Gorin J, Mak L, Amitay Y, Shmeeda H, Zalipsky S.
    Cancer Chemother Pharmacol; 2010 May 05; 66(1):43-52. PubMed ID: 19779718
    [Abstract] [Full Text] [Related]

  • 17. Sustained liver targeting and improved antiproliferative effect of doxorubicin liposomes modified with galactosylated lipid and PEG-lipid.
    Wang S, Xu H, Xu J, Zhang Y, Liu Y, Deng YH, Chen D.
    AAPS PharmSciTech; 2010 Jun 05; 11(2):870-7. PubMed ID: 20490957
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Improvement in the drug delivery and anti-tumor efficacy of PEGylated liposomal doxorubicin by targeting RNA aptamers in mice bearing breast tumor model.
    Moosavian SA, Abnous K, Badiee A, Jaafari MR.
    Colloids Surf B Biointerfaces; 2016 Mar 01; 139():228-36. PubMed ID: 26722819
    [Abstract] [Full Text] [Related]

  • 20. Mild hyperthermia triggered doxorubicin release from optimized stealth thermosensitive liposomes improves intratumoral drug delivery and efficacy.
    Li L, ten Hagen TL, Hossann M, Süss R, van Rhoon GC, Eggermont AM, Haemmerich D, Koning GA.
    J Control Release; 2013 Jun 10; 168(2):142-50. PubMed ID: 23524188
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 26.